David W. Carley
Directeur Technique/Scientifique/R&D chez Pier Pharmaceuticals, Inc.
Profil
David W.
Carley is currently the Director & Chief Scientific Officer at Pier Pharmaceuticals, Inc. and a Professor at the University of Illinois.
He was formerly a Director at RespireRx Pharmaceuticals, Inc. Carley received a doctorate degree from Harvard University in 1985, a doctorate degree from Massachusetts Institute of Technology, and a graduate degree from Massachusetts Institute of Technology in 1982.
Postes actifs de David W. Carley
| Sociétés | Poste | Début |
|---|---|---|
Pier Pharmaceuticals, Inc.
 Pier Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology Pier Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company which develops a pharmacologic treatment for obstructive sleep apnea (OSA). It develops Dronabinol a synthetic derivative of the naturally occurring substance in the cannabis plant, namely delta-9-tetrahydrocannabinol, otherwise known as delta-9 THC. The company was founded in 2007 and is headquartered in Louiseville, CO. | Directeur Technique/Scientifique/R&D | 29/06/2011 |
| University of Illinois | Corporate Officer/Principal | 29/06/2011 |
Anciens postes connus de David W. Carley
| Sociétés | Poste | Fin |
|---|---|---|
| RESPIRERX PHARMACEUTICALS INC. | Directeur/Membre du Conseil | - |
Formation de David W. Carley
| Massachusetts Institute of Technology | Graduate Degree |
| Harvard University | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| RESPIRERX PHARMACEUTICALS INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Pier Pharmaceuticals, Inc.
Pier Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology Pier Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company which develops a pharmacologic treatment for obstructive sleep apnea (OSA). It develops Dronabinol a synthetic derivative of the naturally occurring substance in the cannabis plant, namely delta-9-tetrahydrocannabinol, otherwise known as delta-9 THC. The company was founded in 2007 and is headquartered in Louiseville, CO. | Health Technology |
